



VACCINE INSIGHTS

Your content marketing partner for life sciences

MEDIA KIT 2024





Your content
marketing
partner for life
sciences

INDEX

▶ About	3
▶ What can we do for you?	5
▶ User demographics	7
▶ Editorial calendar	11
▶ Opportunities	12
▶ Webinars	13
▶ Expert roundtables	16
▶ Articles	17
▶ Interviews & podcasts	18
▶ Video presentations	20
▶ Infographics	22
▶ Scientific illustrations	23
▶ eBlasts	24
▶ Premium services	25
▶ Our other publications	26

ABOUT

An online, peer-reviewed, open access journal with a translational focus

Vaccine Insights

Vaccine Insights is a peer-reviewed, open-access journal providing detailed coverage of the development and manufacture of novel vaccines. The journal brings together leading experts from pharma, biotech, academia, NGOs, and other key stakeholders to address critical issues and put the latest developments into context. Guided by an expert advisory board, the journal covers the most important advances in vaccine R&D and delivery across all disease areas.

All content is available free of charge, and the written material is complemented by engaging formats such as webinars, infographics, animations, video, and podcasts.



Is it important for **your company to demonstrate its capabilities** to scientists and/or business leaders making key technology platform decisions at an early stage of a vaccine's development?

Do you need to **generate qualified leads** from companies involved in viral vector or mRNA vaccine development?

Are you looking to **provide educational materials** to individuals focused on preclinical, process, or clinical development?

***Vaccine Insights* provides a unique online content marketing and lead-generation opportunity:**

- ▶ **Active engagement of key stakeholders** from across the global community all year round
- ▶ The chance to **target organizations at varying stages of the R&D pipeline**: Universities, spin-outs, biotechs, pharma, governments and NGOs, investors, and analysts
- ▶ An **alternative to the ever-more expensive conference market**
- ▶ A means by which you can **access the people making the key new discoveries**, those individuals driving the delivery of safe and effective vaccines to patients, and those manufacturing the novel vaccines of the future



Vaccine Insights
provides a unique
online content marketing
and lead-generation
opportunity

WHAT CAN WE DO FOR YOU?

We can:

- ▶ Provide support in the **development of your content marketing strategy** and tactics for this sector, partnering with you in the development of your annual marketing plans
- ▶ Work closely with you to **create quality written, video, and audio content** of high value to your target audience
- ▶ Offer you opportunities to **re-purpose scientific and educational content** you have already developed and make it available to a global audience
- ▶ **Raise your company's profile**, demonstrate your capabilities, and enhance your reputation as a thought-leader in the sector
- ▶ Play a key role in your **lead-generation activities**
- ▶ Ensure your leading scientists are seen as **Subject Matter Experts** throughout your target market
- ▶ **Create written content from video or audio**, ideal for increasing the reach, longevity and searchability of your data and other technical information

We don't sell off-the-shelf solutions. All the packages we provide are tailored to your precise marketing, educational, and business development objectives.

We can partner with you to develop high-quality content to demonstrate your thought-leadership:

- ▶ Your own special focus issue or ebook on the topic of your choice
- ▶ Client case studies, interviews, and co-presentations
- ▶ Peer reviewed articles, as well as editorials and commentaries
- ▶ Video presentations and roundtables
- ▶ Podcasts
- ▶ Infographics and animations
- ▶ Webinars, both live and on demand



USER DEMOGRAPHICS

Data by sector


- ▶ Biotech companies, including those at a relatively early stage of development.
- ▶ Prolific academic institutions, in particular those researching and testing new vaccines and vaccine-related technologies.
- ▶ Pharmaceutical companies and large biotechs with a major or growing focus on vaccines
- ▶ Government-funded organizations (such as BARDA) and NGOs such as Bill & Melinda Gates Foundation, PATH and IAVI
- ▶ Investors and analysts
- ▶ Solution and service providers



28%
Biotech



22%
Academic



18%
Large Vaccine
Manufacturer



8%
Government,
NGO, Public
Health Body



2%
Investor/
Analyst




22%
Solution/
Service Provider

We
currently
have 7,000
registered
users


Data by interest area & seniority

Vaccine Insights has a translational focus, featuring content of value to individuals along the R&D pipeline

- ▶ Discovery and basic research
- ▶ Preclinical development and translational R&D
- ▶ Clinical research
- ▶ Product development, process development, operations, logistics, and manufacture
- ▶ Regulatory affairs, QA/QC and validation
- ▶ Business development, corporate management, and licensing
- ▶ Formulation and delivery device development
- ▶ Public health and market access



Data by interest area & seniority (continued)



Data by location



EDITORIAL CALENDAR 2024

FEBRUARY

Respiratory diseases

- ▶ What's next for COVID vaccines?
 - ▶ prospects for developing next-gen vaccines capable of generating durable, broad-based antibody and T cell immunity
- ▶ Respiratory syncytial virus (RSV):
 - ▶ what will be the impact of newly approved RSV vaccines?
 - ▶ determining the most appropriate schedule of RSV and other respiratory vaccines to maximize uptake and effectiveness
- ▶ Invasive pneumococcal disease:
 - ▶ the impact of new low-cost vaccines in a competitive market
 - ▶ the race for higher valency—where is the limit?
 - ▶ harmonizing pneumococcal vaccine schedules
- ▶ Quantifying the risk from avian influenza and developing vaccines

APRIL

Manufacturing: upstream & raw materials

- ▶ How can manufacturers mitigate supply chain disruption?
- ▶ Localized versus centralized manufacturing
- ▶ Optimizing manufacturing footprint:
 - ▶ in-house manufacturing versus CMO
 - ▶ could combined/flexible facilities improve efficiency?
- ▶ Scaling up vaccine manufacturing
- ▶ Novel expression systems for vaccine production
- ▶ Toward 100% chemically defined media, and easier generation of chemically defined media for individual processes
- ▶ Stainless steel versus single-use bioreactors for vaccine manufacture
- ▶ Maintaining "warm base" capacity for pandemic preparedness
- ▶ Challenges for training and tech transfer in vaccine manufacturing

MAY

RNA vaccines: research directions

- ▶ What will be the next testing ground for RNA vaccines? Where, when, and how will it prove its capabilities, and how much optimization will be needed on a case-by-case basis?
- ▶ Will RNA be broadly applicable or only suited to narrow applications such as pandemic vaccines?
- ▶ Evolving knowledge on mechanisms of action—decreasing reactogenicity while retaining potency
- ▶ Modifying mRNA vaccines to induce mucosal immune responses
- ▶ Adapting mRNA for use in personalized cancer vaccines
- ▶ How will the drive towards cancer vaccines impact infectious disease applications?
- ▶ Latest on next-gen RNA vaccine platforms
- ▶ Regulatory expectations for RNA vaccines—a platform technology?

JUNE

Understanding & enhancing immune responses

- ▶ Addressing immune imprinting/original antigenic sin for COVID-19 and other circulating RNA viruses
- ▶ Advances in immune profiling and understanding mechanisms of action:
 - ▶ profiling immune cells with single-cell analysis tools
 - ▶ applying tools such as NGS, flow cytometry, CyTOF
- ▶ Systems serology to decode vaccine-induced immune responses
- ▶ Understanding individual immune response to vaccination
- ▶ Standardizing data recording, storage, and sharing
- ▶ Embracing AI and machine learning for resolving immunological data and antigen design
- ▶ Understanding and targeting mucosal immunity
- ▶ Novel adjuvants, adjuvant platforms, and combinations

JULY

CMC & analytics

- ▶ Greater connection of CMC with clinical design and understanding quality expectations to avoid bottlenecks
- ▶ How will control strategy evolve with digital twin and digitalization?
- ▶ Patient-centric specifications
- ▶ What is needed from a CMC perspective to achieve CEPI's 100 days goal for pandemic vaccines? Risk-based approaches and innovations
- ▶ Advances in process analytical technology:
 - ▶ monitoring online in real-time
 - ▶ overcoming limitations of current technology (e.g., sensitivity)
 - ▶ lowering barriers for implementation
 - ▶ increased automation
- ▶ High-throughput tools for process development and analytics—forward-looking methods while remaining QC-compliant

SEPTEMBER

Preclinical & clinical research

- ▶ Closing the gap between preclinical and clinical results: better animal and in vitro models
- ▶ Measuring a wider range of immune markers
- ▶ Could evidence from human infection models support approvals?
- ▶ Clinical trials in populations with varied levels of immune competence
- ▶ Correlates of protection—regulators and licensure criteria
- ▶ Vaccine development for special populations
- ▶ Use of AI to clean up clinical data sets and reduce protocol deviations
- ▶ Making the most of real-world vaccine efficacy data
- ▶ Safety—understanding adverse events after vaccination
- ▶ What is a platform technology and how will they be regulated?
- ▶ Regulatory harmonization between regions

OCTOBER

RNA vaccines: formulation & production

- ▶ Sourcing and supply of raw materials—addressing the cost of goods
- ▶ Addressing expense, manufacturing complexity, and IP hurdles of LNPs with next-gen delivery particles
- ▶ Toward temperature-stable formulations
- ▶ Overcoming hurdles in production:
 - ▶ traditional versus cell-free plasmid DNA production
 - ▶ streamlining IVT and capping
 - ▶ optimizing purification, especially of larger RNA constructs—chromatography, TFF
- ▶ Analytical methods and control strategy for mRNA-LNPs:
 - ▶ evolving tools (e.g., NGS and mass spectrometry) for characterization
 - ▶ moving to next-gen assay panels, specific to RNA products
 - ▶ improved methods for detecting residual dsRNA (e.g., dPCR)

NOVEMBER

Manufacturing: downstream, fill/finish, & delivery

- ▶ Exploring the need for better purification solutions across platforms
- ▶ The environmental sustainability of vaccine manufacturing operations
- ▶ Shared challenges and solutions for vaccines, biologics, and advanced therapy manufacturers
- ▶ Addressing extremes of volume:
 - ▶ challenges of small-scale cancer vaccine production
 - ▶ efficient scale-up to meet pandemic preparedness needs
- ▶ Challenges and solutions in cold chain/controlled temperature chain:
 - ▶ routine and corrective maintenance
 - ▶ sustainability
 - ▶ role of automation and AI

Vaccine Insights provide you with fantastic opportunities to:

- ▶ **Educate your target market** about your company's expertise, capabilities, and experience
- ▶ **Share your latest data** with organizations looking for partners and service providers in your field
- ▶ **Profile your executives and scientists** as thought-leaders and KOLs
- ▶ **Generate qualified leads** from across the global sector
- ▶ **Increase awareness** of your company's role in vaccines R&D

OPPORTUNITIES

We offer a broad range of options to help you reach your target audience, any of which can be tailored to match your current marketing and business development priorities. These include interviews, expert roundtables, podcasts, webinars, articles, video presentations, infographics, eblasts, and more.

Any of our options can be tailored to match your current marketing and business development priorities.



WEBINARS

Presenting a webinar with *Vaccine Insights* gives you an efficient and cost-effective way to:

- ▶ Generate qualified leads from amongst the vaccine community
- ▶ Demonstrate your company's expertise and capabilities
- ▶ Stimulate discussion around a topic of significant importance to your customers
- ▶ Educate individuals on crucial regulatory, scientific, or technical issues
- ▶ Make a noise around a new product or service offering launch

Webinars can stand alone or can be included in a Spotlight, depending on the topic and timing fit.

Our
2024
webinar
schedule is
filling up fast.

Contact n.mccall@insights.bio to
discuss options & availability.



Presenting a webinar with us is an efficient and cost-effective way to generate qualified leads.

Our webinar packages include:

- ▶ As much support as you need in terms of topic selection and agenda development, format selection, and speaker panel identification and invitation
- ▶ Full hosting and technical support, including planning calls with panellists and rehearsals as needed
- ▶ A comprehensive promotional plan, including multiple email shots to our database, website and newsletter marketing, and social media
- ▶ A moderator from our editorial team to ensure the webinar runs smoothly on the day
- ▶ Registration and attendee lists for the webinar
- ▶ A report on the questions submitted during the live webinar so you can follow up directly with individuals afterwards and continue the discussion
- ▶ Hosting of the webinar recording on an indefinite basis with ongoing lead generation
- ▶ Webinar recording provided to you for hosting on your own site
- ▶ The option for us to publish an article based on the transcript of the webinar, repurposing your presentation into written format and making it search engine friendly

We don't sell off-the-shelf solutions. All the packages we provide are tailored to your precise marketing, educational and business development objectives.

Examples of previous webinars for our clients:

Mar 15 2023
ON DEMAND
Enabling rapid vaccine development through manufacturing innovation and process efficiency
Wednesday 08:00 PDT / 11:00 EDT / 15:00 GMT / 16:00 CET
Sponsor
ThermoFisher SCIENTIFIC

VACCINESIGHTS
EXPERT ROUNDTABLE
Enabling rapid vaccine development through manufacturing innovation & process efficiency

Charlotte Barker, Editor, Vaccine Insights, speaks to *Biocultural* and *Health Care Roundtable*, Professor of Biological Systems Engineering, Imperial College London, Kunal Shah, Managing Director, Vaccines, Novartis, Alan Thompson, Director, Vaccine Science, and Steve Attig, Director, Process R&D, Merck.

Panel-style webinar with accompanying roundtable article for Thermo Fisher Scientific

Aug 23 2023
ON DEMAND
Achieving vaccine equity: challenges and opportunities of multi-modality manufacturing
Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Sponsor
cytiva

Watch now

SPEAKERS
Katarina Steniko
Enterprise Solutions Commercial Activation Leader at Cytiva


Presentation-style webinar with Q&A for Cytiva

Oct 4 2023
ON DEMAND
The growing case for stainless steel versus single-use in mRNA vaccine production
Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Sponsor
CRB

Watch now

SPEAKERS
Steve Attig
Fellow - Bioprocess Design at CRB

Live30 webinar: a 30 minute webinar focused on new technologies and their applications for CRB



You can view all of our on-demand webinars here.

EXPERT ROUNDTABLES

On-demand video expert roundtables provide powerful tools for you to generate qualified leads and/or position your thought-leader(s) at the heart of the debate around a topic of key importance to your company.

Our editorial team works closely with you to identify over-arching topics and discussion points, and to convene a panel of KOLs. We then liaise with the panel to define the final list of questions for discussion, video and edit the roundtable itself, and then produce a full article based on the transcript.



Video roundtable examples:



Video



Article

Expert Roundtable: leveraging cutting edge tools to convert I-O data into knowledge



Video and article



Poster summarising key learning points


Strategies for scaling up and out in gene therapy manufacturing: addressing AAV's growing pains (for Corning)

ARTICLES

Free access publication of submitted articles remains the gold standard for sharing data with scientists across the sector.

Our sponsored article publication package includes full peer review, a license for you to reproduce the article on your own website, and a comprehensive two-month promotional package to maximise readership.

Examples of articles for our clients:




Validating a rapid analytical method for plasmid purity harmonization
Vaccine Insights 2023; 2(2), 33-43
DOI: 10.18609/vac.2023.007
PUBLISHED: 2 MAY
INNOVATOR INSIGHT
Joe Ferraliolo

Vaccines and gene therapies require a significant DNA supply. Plasmid DNA (pDNA) is produced in stainless-steel bioreactors. The process is inherently slow and expensive, with limited capacity for manufacturing optimization opportunities at each step of the pDNA workflow, through fermentation and purification. The integration of well-designed technologies and process control analytical solutions is essential to ensure consistent and high pDNA yield at high qualities. CTEch™ analytical solutions are designed to optimize cycle time, increase process efficiency, strengthen process control, and minimize risk.

FIGURE 2
Rapidly validating a new method for plasmid purity harmonization using a multi-capillary electrophoresis platform. The figure shows a graph of the number of peaks versus time for the multi-capillary electrophoresis platform, comparing it to a standard method. The graph shows a significant reduction in the number of peaks, indicating improved purity and consistency.

TABLE 1
Comparison of the number of peaks for the multi-capillary electrophoresis platform and the standard method. The table shows that the multi-capillary platform consistently results in a lower number of peaks, indicating higher purity.

Validating a rapid analytical method for plasmid purity determination & platform harmonization for Repligen




Accelerating AAV capsid analysis using a new multi-capillary platform
Cell & Gene Therapy Insights 2022; 8(2), 231-240
DOI: 10.18609/cgti.2022.339
PUBLISHED: 16 MARCH 2022
INNOVATOR INSIGHT
Susan Darling

Adeno-associated viral (AAV) vectors, while offering numerous advantages over other viruses can readily enter a variety of cell types), are highly complex molecules that present significant number of serotypes to choose from, and the need to implement transfection processes that are of interest and purification hurdles to overcome. From an analytical perspective, samples and require more complex analytical methods that involve complex method set ups, but results challenges, developers of gene therapies must be able to understand the molecular liabilities of

FIGURE 4
Accelerating AAV capsid analysis using a new multi-capillary platform. The figure shows a graph of the number of peaks versus time for the multi-capillary platform, comparing it to a standard method. The graph shows a significant reduction in the number of peaks, indicating improved purity and consistency.

FIGURE 7
Comparison of the number of peaks for the multi-capillary platform and the standard method. The table shows that the multi-capillary platform consistently results in a lower number of peaks, indicating higher purity.

Accelerating AAV capsid analysis using a new multi-capillary electrophoresis platform for SCIEX



Characterization of a novel high-throughput, high-speed based image cytometric cell counting method
Cell & Gene Therapy Insights 2021; 7(4), 427-447
DOI: 10.18609/cgti.2021.070
PUBLISHED: 14 MAY 2021
RESEARCH ARTICLE
Jordan Bell, Yongyang Huang, Henry Qazi, Dmitriy Kuksin, Jean Qiu, Bo Lin, Leo

Bioprocessing applications for cells and biologics have dramatically increased the number immunotherapy. The cell counting time is a major bottleneck for traditional counting methods throughput, high-speed, and high-precision system. Here we characterize and demonstrate a novel high-throughput, high-speed and high-precision system. We investigated the head-to-head cell counting

FIGURE 4
Characterization of a novel high-throughput, high-speed based image cytometric cell counting method. The figure shows a flowchart of the cell counting process, from sample preparation to data analysis. It includes a bar chart comparing the cell counting results of the new method to a standard method, showing significantly higher throughput and precision.

TABLE 4
Comparison of the cell counting results for the new method and the standard method. The table shows that the new method consistently results in a higher number of cells counted, indicating improved accuracy and throughput.

Characterization of a novel high-throughput, high-speed and high-precision plate-based image cytometric cell counting method for Nexcelom

INTERVIEWS & PODCASTS

Interviews are a great way to raise awareness within the vaccine community, with minimal resource requirements from your team.

We can interview up to three of your scientists, executives, partners or clients, with the resulting video, podcast and/or written version included in an issue of the online journal.

Examples of previous interviews for our clients:

Video and written

[Stepping foot into a successful partnership to support your viral vector therapy through commercialization for Merck](#)

VECTORS: Downstream Bioprocessing

Stepping foot into a successful partnership to support your viral vector therapy through commercialization for Merck

Cell & Gene Therapy Insights 2021; 7(11): 1706–1710
10.18609/cgti.2021.225
PUBLISHED: 12 JANUARY 2022

Minh Hong, Marc Gaal

Charlotte Barker, Editor, Cell and Gene Therapy Insights, speaks to Minh Hong, Head of Commercialization, Program Management at the Life Sciences Business Sector, Merck

Minh Hong leads the commercial team for Viral Gene Therapy contract Business Sector of Merck. He is responsible for account management,...

INTERVIEW

Q: How does your partnership with Merck support your commercialization efforts? **A:** Merck provides us with a robust manufacturing process that requires process development insights at every stage of the product lifecycle. The manufacturing process is supported by a comprehensive understanding of the underlying science and technology. This allows us to optimize the manufacturing process for the manufacturing facility.

Q: Once you understand the customer's needs, how do you support them through the manufacturing process? **A:** Once the manufacturing process is confirmed, we have already started with single-patient production. We have a strong partnership with the customer and the Merck team. The Merck team helps us with the process of setting up the manufacturing process. We are currently in the process of setting up the manufacturing process. We are currently in the process of setting up the manufacturing process. We are currently in the process of setting up the manufacturing process.

Q: How has your organization chosen to invest in cell and gene therapy manufacturing? **A:** We have invested in a new manufacturing facility. This facility is designed to support the production of viral vector therapies. We have invested in a new manufacturing facility. This facility is designed to support the production of viral vector therapies. We have invested in a new manufacturing facility. This facility is designed to support the production of viral vector therapies.

Q: What has your organization determined to be the right time to invest in a new gene therapy manufacturing facility? **A:** We have determined that the right time to invest in a new gene therapy manufacturing facility is when we have a clear understanding of the customer's needs. We have determined that the right time to invest in a new gene therapy manufacturing facility is when we have a clear understanding of the customer's needs.

Cell & Gene Therapy Insights | ISSN 2099-7900 | 1707

Podcast and written

[Precisely for CGT: automating aseptic filling for lowest volumes for Single Use Support](#)

SUPPLY CHAIN: Best practices for ensuring cell and gene therapy supply chain scalability

Precisely for CGT: automating aseptic filling for lowest volumes for Single Use Support

Cell & Gene Therapy Insights 2022; 8(3): 403–408
DOI: 10.18609/cgti.2021.059
PUBLISHED: 27 MARCH 2022

PODCAST

Barbara Fischer

Róisín McGuigan, Editor, Bioinsights, speaks to Barbara Fischer, Process Consultant, Single Use Support

...do not be afraid of digital transformation. Follow the opportunities that...

PODCAST INTERVIEW

Q: What specific trends are you seeing currently in the selection of primary packaging? **A:** The question is, which primary packages are suitable for all process steps and unit operations, and flexible enough to be used from early development to scale-up?

Q: How do you see the future of aseptic filling? **A:** The future of aseptic filling is to move towards more automation and digitalization. We are currently in the process of setting up the manufacturing process. We are currently in the process of setting up the manufacturing process. We are currently in the process of setting up the manufacturing process.

Q: What are the key challenges in the development of aseptic filling? **A:** The key challenges in the development of aseptic filling are the complexity of the process and the need for high-quality materials. We are currently in the process of setting up the manufacturing process. We are currently in the process of setting up the manufacturing process. We are currently in the process of setting up the manufacturing process.

Cell & Gene Therapy Insights | ISSN 2099-7900 | 405

Podcasts
in a variety
of formats and
lengths can also be
produced, either in
series or as
one-offs



Key factors to consider for successful cell therapy manufacturing: a case study

Cell & Gene Therapy Insights 2022; 8(2): 241-249
10.18609/cgti.2022.039
PUBLISHED: 2 MARCH 2022

Valentina Becherucci, Øystein Åmellem, Xavier de Mollerat du Jeu

You can listen to the [podcast at the bottom of this page](#) or read the interview below

[View pdf](#)



PODCAST INTERVIEW

ØA: That makes sense. When you have a four-week manufacturing time, that means that the cells are undergoing several passages. Do you have criteria for how many passages you run in your manufacturing process, in order to not lose the cells' characteristics? Do you count the number of passages or the way you get to the desired end point of your drug?

VB: The data of all cultures comes out after process validation. The goal is to reach the therapeutic dose. The culture can be shorter - you can stop it at three weeks and use four weeks. It can be more than four weeks because, according to the literature, if you culture for more than that or five weeks, you can get some unwanted effects on cells. For example, you can get genetic variation that is not good for the patient. The four weeks come from our process validation, where we produced five batches of MSCs, and in four batches we saw that the variability was low in terms of the number of cells after four weeks of culture. We also checked other parameters of MSCs, for example the average expression of specific markers that must be positive or negative according to International Society of Cell Therapy.

XMJ: Valentina, in this four-week process, how do you ensure you maintain sterility? Do you do weekly QC monitoring on your process?

VB: In our process, we perform initial sterility before starting the culture directly on the bioreactor. Then, we perform an in-process control of sterility after two weeks of culture, and at the end of the culture, before freezing. In our process, cells will be frozen after four weeks of culture and then stored in liquid nitrogen until you get the patient. In this case, the sterility is performed both on cells and on the cell culture media, on the equipment.

Q DH: What are the QC or analytical tests you implement in your process to ensure the safety and quality of the product?

VB: According to the regulatory specification, the testing methods must be validated, and mandatory regular testing includes testing of the sterility, endotoxin, mycoplasmas, and function, and in our case we also perform cell identification with flow cytometry. All these tests are performed as in-process control at different steps of the process, and also for the final release or the end of the process.

ØA: Valentina - as you are using flasks, you operate in Class A cell culture conditions. I see you used bags, or a more closed system that you could operate in a hood?


VB: We have tested different kinds of flasks with more surface for culture. However, we do not use bags. Bags are only used in the final step for freezing and storage in liquid nitrogen. We only use open systems and flasks.

XMJ: You mentioned it is a Phase 2 process. As you move to Phase 3 and commercial, you will need to scale this process. How are you thinking about doing that?



For example:

Key factors to consider for successful cell therapy manufacturing: a case study for Thermo Fisher Scientific



VIDEO PRESENTATIONS

Our FastFacts videos are 10–15 minute edited presentations, accompanied by a poster summarising the key learning points. They are designed for the presentation of app notes, validation data, case studies, scientific posters, or product demonstrations, and work well both for educational purposes and for lead generation.



Here are some examples:

FASTFACTS

Adenovirus vector manufacturing platform using CIMmultus™ QA assures the supply of safe vaccines

Cell & Gene Therapy Insights 2021, 7(8), 1125
DOI: 10.18609/cgti.2021.1127
PUBLISHED: 9 OCTOBER 2021

FASTFACTS
Hana Jug

Watch the video or read the poster to learn:

- ▶ Why downstream processing remains one of the main barriers to commercial-scale production of adenoviral vectors
- ▶ How an adenoviral vector purification platform using CIMmultus™ QA offers high capacity and high yields of adenoviral vectors

Hana Jug is a Project Manager in process

FASTFACTS

Adenovirus vector manufacturing platform using CIMmultus™ QA assures the supply of safe vaccines

Hana Jug, Birkbeck University of London, London, UK

Production processing of adenoviral vectors is a complex task. The use of CIMmultus™ QA offers a platform for purification of adenoviral vectors using a novel three-step purification process. This process is designed to ensure high yields and high purity of adenoviral vectors, which is essential for the production of safe vaccines.

CELL & GENE THERAPY INSIGHTS | **POSTER**

Adenovirus vector manufacturing platform using CIMmultus™ QA assures the supply of safe vaccines for Sartorius

FASTFACTS

Plasmid processing for mRNA, gene therapy and other vector applications

Cell & Gene Therapy Insights 2021, 7(6), 723
DOI: 10.18609/cgti.2021.103
PUBLISHED: 30 JUNE 2021

FASTFACTS
Henrik Iltre

Watch the video or read the poster to learn:

- ▶ Novel three-step purification process for plasmid processing
- ▶ A new high-productivity multimodal resin design
- ▶ Comparison between legacy and novel purification processes
- ▶ How a novel filter format could offer even greater yields

Henrik Iltre has his roots in specific. He is motivated by the challenges of Cytiva. He is a Project Manager in process

FASTFACTS

Plasmid processing for mRNA, gene therapy and other vector applications

Henrik Iltre, Cytiva, Uppsala, Sweden

The use of CIMmultus™ QA offers a platform for purification of plasmids using a novel three-step purification process. This process is designed to ensure high yields and high purity of plasmids, which is essential for the production of mRNA, gene therapy and other vector applications.

CELL & GENE THERAPY INSIGHTS | **POSTER**

Plasmid processing for mRNA, gene therapy and other vector applications for Cytiva

FASTFACTS

Collaboration to develop modular facility proof-of-concept for multi-modal bioprocessing activities

Vaccine Insights 2022, 1(6), 325
DOI: 10.18609/vi.2022.045
PUBLISHED: 18 JANUARY 2022

FASTFACTS
Jerome Dallin, Thomas Hauser

Watch the video or read the poster to learn about:

- ▶ Why modular, multi-modal bioprocessing is an important approach for the development of multi-modal bioprocessing facilities
- ▶ The specific design and timelines for the proof-of-concept
- ▶ How this modular facility approach can be leveraged for the development of multi-modal bioprocessing facilities
- ▶ A roadmap for the future, including improved sustainability

FASTFACTS

Collaboration to develop modular facility proof-of-concept for multi-modal bioprocessing activities

Jerome Dallin, Birkbeck University of London, London, UK; Thomas Hauser, Merck, Darmstadt, Germany

The use of modular, multi-modal bioprocessing facilities offers a platform for the development of multi-modal bioprocessing facilities. This approach is designed to ensure high yields and high purity of products, which is essential for the development of multi-modal bioprocessing facilities.

VACCINE INSIGHTS | **POSTER**

Collaboration to develop modular facility proof-of-concept for multi-modal bioprocessing activities for Merck

FASTFACTS

End-to-end solutions for mRNA development and manufacturing

Vaccine Insights 2022, 1(6), 279
DOI: 10.18609/vi.2022.039
PUBLISHED: 21 NOVEMBER 2021

FASTFACTS
Susana Domingues-Vallion

Watch the video or read the poster to learn about:

- ▶ Common challenges in the development and commercialization of mRNA
- ▶ The advantage of choice - why filling only your own shoes
- ▶ Summary of key foundational analytical and characterization challenges

Susana Domingues-Vallion is currently a Senior Lecturer in Cell Biology from the University of Trás-os-Montes e Alto Douro. Susana has 13 years of experience in the pharmaceutical industry. She is motivated by the challenges of Cytiva. She is a Senior Lecturer in process

FASTFACTS

End-to-end solutions for mRNA development and manufacturing

Susana Domingues-Vallion, Cytiva, Vila Real, Portugal

The use of end-to-end solutions for mRNA development and manufacturing offers a platform for the development of mRNA. This approach is designed to ensure high yields and high purity of mRNA, which is essential for the development of mRNA.

VACCINE INSIGHTS | **POSTER**

End-to-end solutions for mRNA development and manufacturing for Thermo Fisher Scientific

Our FastFacts work well for educational and lead-generation purposes

INFOGRAPHICS

Our team are experts in communicating complex scientific information via visual formats, including infographics (static, voiced, and animated), PPT presentations, and illustrations. They work closely with your team to define contents and style, and the resulting content can be published in *Vaccine Insights* or simply provided to you for your own use.



Examples include:

Voiced infographic

[Manufacturing and analytics for lentivirus and AAV vectors: a visual and audio guide for Thermo Fisher Scientific](#)







Animated infographic

[Regulatory FAQs & common concerns for cell & gene therapy raw and starting materials for Thermo Fisher Scientific](#)



SCIENTIFIC ILLUSTRATIONS



We work from your sketch or concept to create schematics or illustrations of your products or services

eBLASTS

We offer a strictly limited number of third-party eblasts to our registered users.


Our 2024 schedule is open for bookings. Please contact **Nicola McCall** at n.mccall@insights.bio.




PREMIUM SERVICES

We offer a number of premium options, both for content creation and for market research. These include:


- ▶ Bringing together KOL panels to discuss the topics of your choice, publishing the output as an ebook, video and written roundtable, or other suitable content format
- ▶ Designing infographics, which can be animated and/or voiced, ideal for communicating complex technical or scientific information in an easily digestible format
- ▶ Inviting industry or academic Subject Matter Experts to join your live webinars to add their opinions to the discussion
- ▶ Building and deploying surveys amongst our users, providing detailed reports on the responses
- ▶ Bringing together focus groups to discuss your products/services, or topics of interest to you.




mRNA manufacturing and analytics




DNA TEMPLATE PREPARATION



mRNA SYNTHESIS



STREAMLINE PURIFICATION



OUR OTHER PUBLICATIONS


In addition to *Vaccine Insights*, BioInsights also publishes:



Cell & Gene Therapy Insights

Launched in 2014, *Cell & Gene Therapy Insights* is our inaugural online, open access, peer-reviewed journal with a translational focus.


Cell & Gene Therapy Insights addresses the important challenges and advances in the field of cell and gene therapy, publishing original research, reviews, commentary articles, clinical trial reports, and much more.



Immuno-Oncology Insights

Immuno-Oncology Insights is an open access, independently peer reviewed publication specifically designed to fill a number of clear and important gaps in the current slate of journals for the industrial and academic immuno-oncology communities.

Guided by an editorial board lead by Jon Wigginton and Renier J. Brentjens, *Immuno-Oncology Insights* places R&D challenges and progress across a wide variety of technology fields in context.



Nucleic Acid Insights

The latest addition to our publication portfolio, *Nucleic Acid Insights* provides online, peer-reviewed, open access content with a translational focus.

Nucleic Acid Insights is specifically designed to provide the need-to-know information required to successfully navigate this rapidly evolving space, covering all the major RNA and DNA technologies and modalities, including but not limited to: messenger RNA (mRNA); plasmid DNA; antisense oligonucleotides (ASO); phosphorodiamidate morpholino oligonucleotides (PMO); RNA interference (RNAi); small interfering RNA (siRNA); aptamers; micro RNA (miRNA); and guide RNA (gRNA).